Physician profile
Lana Schmidt
NPI 1245260082
$1,300,979.13
in general payments reported to CMS, 2019-2025
21 companies · $206K in 2025
The $206K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246K · 2020: $97K · 2021: $97K · 2022: $196K · 2023: $227K · 2024: $234K · 2025: $206K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $570K · Consulting Fee: $40K · Travel and Lodging: $33K · Food and Beverage: $15K · Honoraria: $7,800 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $570,148.00 |
| Consulting Fee | $40,049.50 |
| Travel and Lodging | $33,136.10 |
| Food and Beverage | $14,902.28 |
| Honoraria | $7,800.00 |
| Education | $271.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $252,601.50 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $246,845.15 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $208,962.92 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $103,724.71 | 2022-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $97,817.20 | 2019-2022 | |
| Janssen Biotech, INC. | $88,707.37 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Celgene Corporation | $81,458.87 | 2019-2020 | |
| Dermavant Sciences, INC. | $80,879.12 | 2023-2024 | Vtama |
| Ucb, INC. | $74,234.45 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $31,773.04 | 2019-2025 | |
| Incyte Corporation | $13,964.62 | 2021-2022 | |
| Organon LLC | $9,737.49 | 2025 | Vtama |
| Genzyme Corporation | $7,289.97 | 2020-2024 | |
| Helsinn Therapeutics (U.S.), INC. | $1,482.00 | 2020 | |
| Pfizer INC. | $628.61 | 2019-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $368.10 | 2019-2024 | Dupixent |
| Galderma Laboratories, L.P. | $217.55 | 2021-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $119.12 | 2019-2023 | Odomzo, Blu-U, Winlevi |
| Arcutis Biotherapeutics, INC. | $89.34 | 2023-2024 | Zoryve |
| Stemline Therapeutics INC. | $57.11 | 2021 | |
| Biofrontera INC. | $20.89 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lana Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.